Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

April 9, 2021

Primary Completion Date

September 9, 2022

Study Completion Date

September 9, 2022

Conditions
Meningococcal Vaccine
Interventions
BIOLOGICAL

Nimenrix

MenACWY-TT vaccine

Trial Locations (16)

15706

CHUS - Hospital Clinico Universitario, Santiago de Compostela

20520

Turku Vaccine Research Clinic, Turku

28050

Hospital Universitario HM Sanchinarro, Madrid

33100

Tampere Vaccine Research Clinic, Tampere

41012

Instituto Hispalense de Pediatria, Seville

04400

Jarvenpaa Vaccine Research Center, Järvenpää

Jarvenpaa Vaccine Research Center, Järvenpää

02230

Espoo Vaccine Research Clinic, Espoo

00100

FVR, Etelä-Helsingin rokotetutkimusklinikka, Helsinki

Helsinki South Vaccine Research Clinic, Helsinki

00930

Helsinki East Vaccine Research Clinic, Helsinki

85-048

IN VIVO Bydgoszcz, Bydgoszcz

85-079

NZOZ Przychodnia Vitamed, Bydgoszcz

30-348

Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o., Krakow

91-347

GRAVITA. Diagnostyka i Leczenie nieplodnosci, Lodz

55-100

Szpital im. Św. Jadwigi Śląskiej w Trzebnicy, Trzebnica

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04819113 - Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age | Biotech Hunter | Biotech Hunter